Early Launch Metrics for Janssen’s Tremfya May Lag Those of Lilly’s Taltz at a Similar Post-Launch Period, but Signs Indicate the New IL-23 Inhibitor is Poised to Set a New Bar for Efficacy in Skin
According to Spherix Global Insight’s latest quarterly release of RealTime Dynamix™: Psoriasis, dermatologists are feeling increasingly overwhelmed with the sheer number of new biologic entrants recently approved in the US. Download Report Overview EXTON, Pa., Sept. 14, 2017 /PRNewswire/ — At just over one-month post launch, more dermatologists were aware of Taltz’s approval compared to […]
US Gastroenterologists May Thwart Uptake of New Biosimilars, Such as Pfizer’s Inflectra and Merck/Samsung Bioepis’ Renflexis, by Choosing an Alternative TNF-Inhibitor, Such as AbbVie’s Humira
Despite Remicade’s status as the go-to agent in ulcerative colitis (UC), the introduction and adoption of the biosimilar Inflectra appears to be having an impact on the brand, with share for Janssen’s branded infliximab significantly down compared to the same period last year, according to a recent report from Spherix Global Insights Download Report Overview […]
Uptake of Sanofi/Regeneron’s Dupixent for Atopic Dermatitis Strong, but Sales Representative Contact Rates Leave Something to be Desired
At roughly four months post-launch, the Dupixent patient and user base has experienced substantial growth, though nearly one-third of US dermatologists have yet to see a sales representative according to recent report from Spherix Global Insights Download Report Overview EXTON, Pa., Aug. 21, 2017 /PRNewswire/ — According to the Q3 update of RealTime Dynamix™: Atopic […]
Cosentyx Plateaus as Non-TNF Agents Prepare to Dominate in Psoriatic Arthritis
From: Specialty Pharma Time By: Lauren Santye Although there are a growing number of rheumatologists in the United States who report the use of Cosentyx to treat psoriatic arthritis (PsA), the increasing user base has failed to translate into overall increases in biologic share, according to market research company Spherix Global Insights. The plateau of […]
RealTime Dynamix™: Atopic Dermatitis US Q3
Atopic dermatitis (AD), the most common form of eczema affecting 5 to 20% of the worldwide population, is a chronic inflammatory disease often presenting as a skin rash. Moderate-to-severe AD is characterized by rashes often covering much of the body, and can include intense itching and dryness, crusting, redness, and oozing which can be debilitating. […]
Novartis’ Cosentyx Beginning to Plateau in Psoriatic Arthritis, as US Rheumatologists Prepare for an Influx of Non-TNF Agents, Such as BMS’ Orencia, Pfizer’s Xeljanz, and Lilly’s IL-17, Taltz
Despite an increasing user base, Cosentyx share has remained unchanged over the past six months, according to recently released data from Spherix Global Insights Download Report Overview EXTON, Pa., Aug. 15, 2017 /PRNewswire/ — In the most recent quarterly update of RealTime Dynamix™ Psoriatic Arthritis, a growing population of US rheumatologists (n=101) are reporting use […]
Early US dermatologist’s views of Tremfya leave ground to be covered
From: The Pharma Letter Early US dermatologist’s views of Tremfya leave ground to be covered At two weeks post launch, only half of the surveyed US dermatologists (n=104) were aware of Tremfya’s (guselkumab) approval when aided. The drug was approved by the US Food and Drug Administration on July 13 as a treatment for moderate […]
Changes Afoot in the Management of CKD Mineral Bone Disorder Reinforced by a Clinical Practice Guideline Update from KDIGO
According to RealTime Dynamix™: Bone and Mineral Metabolism, a quarterly report published by Spherix Global Insights, the migration to non-calcium based binders, with accelerated adoption of Keryx’s Auryxia and FMC’s Velphoro, is expected to continue Download Report Overview EXTON, Pa., Aug. 10, 2017 /PRNewswire/ — Since the introduction of Renagel by Genzyme Corporation nearly 20 […]
RealWorld Dynamix™: Biologic/JAK Switching in RA US 2017
There are currently nine biologics, one biosimilar, and one oral janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis (RA) in the United States. With the more established TNF-inhibiting biologics on the market for nearly two decades, RA treatment protocol and payer policy tend to dictate their use as first-line biologics. However, rheumatologists […]
RealTime Dynamix™: Inflammatory Bowel Disorder US Q3
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), and Crohn’s Disease (CD) currently affects the lives of approximately 1.6 million Americans. The use of biologics has changed the face of treatment for moderate-to-severe IBD patients. However, recent launches, an active pipeline, and the introduction of biosimilars present an opportunity for major future shifts in the IBD […]
